A history of mild liver disease is associated with a higher risk for bleeding during anticoagulation therapy but does not change the relative efficacy and safety of edoxaban compared with warfarin in patients with atrial fibrillation.
Non-vitamin K oral anticoagulants reduce hemorrhagic stroke and intracranial hemorrhage risks vs vitamin K antagonists in patients with end-stage renal disease and atrial fibrillation.
Investigators evaluated the effectiveness of spironolactone to decrease new-onset atrial fibrillation in patients with symptomatic heart failure with preserved ejection fraction.
For patients with AF, the efficacy and safety of edoxaban versus warfarin is not altered with a history of liver disease.
A regimen of non-VKA oral anticoagulants plus P2Y12 inhibitor for patients with atrial fibrillation undergoing percutaneous coronary intervention was associated with fewer bleeding events when compared with VKA plus dual antiplatelet therapy.
A recent meta-analysis found there is insufficient evidence supporting the link between some forms of subclinical atrial fibrillation and an increased risk of thrombotic events.
Patients with nonspecific intraventricular conduction delay and QRS duration <150 ms or
right bundle branch block may not benefit from cardiac resynchronization therapy with defibrillator, compared with implantable cardioverter-defibrillator therapy alone.
Oral anticoagulant use has a preventive effect on dementia development in patients with incident atrial fibrillation.
Use of pantoprazole for up to three years to prevent upper gastrointestinal events in patients receiving anticoagulant therapy with aspirin and/or rivaroxaban has a similar safety profile to placebo except for an increased risk for enteric infections.
Increasing vitamin K intake through dietary strategies improves the anticoagulation stability of warfarin-treated patients.
